Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.

Hdl Handle:
http://hdl.handle.net/10147/207600
Title:
Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.
Authors:
Duffy, M J; Sturgeon, C; Lamerz, R; Haglund, C; Holubec, V L; Klapdor, R; Nicolini, A; Topolcan, O; Heinemann, V
Affiliation:
Department of Pathology and Laboratory Medicine, St Vincent's University, Hospital, Dublin. michael.j.duffy@ucd.ie
Citation:
Ann Oncol. 2010 Mar;21(3):441-7. Epub 2009 Aug 18.
Journal:
Annals of oncology : official journal of the European Society for Medical, Oncology / ESMO
Issue Date:
1-Feb-2012
URI:
http://hdl.handle.net/10147/207600
DOI:
10.1093/annonc/mdp332
PubMed ID:
19690057
Abstract:
Pancreatic ductal adenocarcinoma is one of the most difficult malignancies to diagnose and treat. The aim of this article is to review how tumor markers can aid the diagnosis and management of patients with this malignancy. The most widely used and best validated marker for pancreatic cancer is CA 19-9. Inadequate sensitivity and specificity limit the use of CA 19-9 in the early diagnosis of pancreatic cancer. In non-jaundiced patients, however, CA 19-9 may complement other diagnostic procedures. In patients with resectable pancreatic cancer, presurgical and postresection CA 19-9 levels correlate with overall survival. In advanced disease, elevated pretreatment levels of CA 19-9 are associated with adverse patient outcome and thus may be combined with other factors for risk stratification. Most, but not all, reports indicate that serial levels of CA 19-9 correlate with response to systemic therapy. Use of CA 19-9 kinetics in conjunction with imaging is therefore recommended in monitoring therapy. Although several potential serum and tissue markers for pancreatic cancer are currently undergoing evaluation, none are sufficiently validated for routine clinical use. CA 19-9 thus remains the serum pancreatic cancer marker against which new markers for this malignancy should be judged.
Language:
eng
MeSH:
Humans; Pancreatic Neoplasms/diagnosis/*metabolism/therapy; Tumor Markers, Biological/*metabolism
ISSN:
1569-8041 (Electronic); 0923-7534 (Linking)

Full metadata record

DC FieldValue Language
dc.contributor.authorDuffy, M Jen_GB
dc.contributor.authorSturgeon, Cen_GB
dc.contributor.authorLamerz, Ren_GB
dc.contributor.authorHaglund, Cen_GB
dc.contributor.authorHolubec, V Len_GB
dc.contributor.authorKlapdor, Ren_GB
dc.contributor.authorNicolini, Aen_GB
dc.contributor.authorTopolcan, Oen_GB
dc.contributor.authorHeinemann, Ven_GB
dc.date.accessioned2012-02-01T10:32:31Z-
dc.date.available2012-02-01T10:32:31Z-
dc.date.issued2012-02-01T10:32:31Z-
dc.identifier.citationAnn Oncol. 2010 Mar;21(3):441-7. Epub 2009 Aug 18.en_GB
dc.identifier.issn1569-8041 (Electronic)en_GB
dc.identifier.issn0923-7534 (Linking)en_GB
dc.identifier.pmid19690057en_GB
dc.identifier.doi10.1093/annonc/mdp332en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207600-
dc.description.abstractPancreatic ductal adenocarcinoma is one of the most difficult malignancies to diagnose and treat. The aim of this article is to review how tumor markers can aid the diagnosis and management of patients with this malignancy. The most widely used and best validated marker for pancreatic cancer is CA 19-9. Inadequate sensitivity and specificity limit the use of CA 19-9 in the early diagnosis of pancreatic cancer. In non-jaundiced patients, however, CA 19-9 may complement other diagnostic procedures. In patients with resectable pancreatic cancer, presurgical and postresection CA 19-9 levels correlate with overall survival. In advanced disease, elevated pretreatment levels of CA 19-9 are associated with adverse patient outcome and thus may be combined with other factors for risk stratification. Most, but not all, reports indicate that serial levels of CA 19-9 correlate with response to systemic therapy. Use of CA 19-9 kinetics in conjunction with imaging is therefore recommended in monitoring therapy. Although several potential serum and tissue markers for pancreatic cancer are currently undergoing evaluation, none are sufficiently validated for routine clinical use. CA 19-9 thus remains the serum pancreatic cancer marker against which new markers for this malignancy should be judged.en_GB
dc.language.isoengen_GB
dc.subject.meshHumansen_GB
dc.subject.meshPancreatic Neoplasms/diagnosis/*metabolism/therapyen_GB
dc.subject.meshTumor Markers, Biological/*metabolismen_GB
dc.titleTumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.en_GB
dc.contributor.departmentDepartment of Pathology and Laboratory Medicine, St Vincent's University, Hospital, Dublin. michael.j.duffy@ucd.ieen_GB
dc.identifier.journalAnnals of oncology : official journal of the European Society for Medical, Oncology / ESMOen_GB
dc.description.provinceLeinster-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.